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Abstract
Background: To investigate obstetric prognosis in sisters of preeclamptic women.
Methods:  We identified consecutive 635 sib pairs from the Birth Registry data of Kuopio
University Hospital who had their first delivery between January 1989 and December 1999 in our
institution. Of these, in 530 pairs both sisters had non-preeclamptic pregnancies (the reference
group), in 63 pairs one of the sisters had preeclampsia and the unaffected sisters were studied
(study group I). In 42 pairs both sister's first delivery was affected (study group II). Pregnancy
outcome measures in these groups were compared.
Results:  Unaffected sisters of the index patients had uncompromised fetal growth in their
pregnancies, and overall, as good obstetric outcomes as in the reference group. The data on
affected sisters of the index patients showed an increased prematurity rate, and increased
incidences of low birth weight and small-for-gestational age infants, as expected.
Conclusion: Unaffected sisters of the index patients had no signs of utero-placental insufficiency
and they were at low risk with regard to adverse obstetric outcome, whereas affected sisters were
high-risk. Clinically, affected versus unaffected status appears to be clear-cut in first-degree relatives
regardless of their genetic susceptibility and unaffected sisters do not need special antepartum
surveillance.
Background
Preeclampsia is a leading cause of maternal and perinatal
morbidity and mortality[1] and the disease carries a ten-
dency towards familial clustering [2–6]. Although the pat-
tern of inheritance is not yet resolved, investigations into
the genetic etiology of preeclampsia have yielded intrigu-
ing results implying that genes are responsible for the dis-
ease rather than shared environment [7]. Current
concepts favor the hypothesis, that preeclampsia results
from interplay of multiple genes and the environment,
the disease being a polygenic trait with a strong maternal
contribution [8]. First-degree relatives are known to have
a fivefold increased risk of developing the disease com-
pared with women with no family history of preeclamp-
sia. Women above a certain threshold of this trait manifest
the disease, whereas those below the threshold have a
normal phenotype [9]. As far as we are aware of, studies
looking at the obstetric outcome in unaffected sisters are
still lacking. This study was undertaken to evaluate preg-
nancy outcome in unaffected sisters of preeclamptic wom-
en, to find out whether their genetic susceptibility is
associated with adverse outcome. Such data is useful not
only for scientific but also for counselling purposes.
Published: 23 February 2003
BMC Women's Health 2003, 3:1
Received: 20 October 2002
Accepted: 23 February 2003
This article is available from: http://www.biomedcentral.com/1472-6874/3/1
© 2003 Heiskanen et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Women’s Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/1
Page 2 of 5
(page number not for citation purposes)
Methods
The study was approved by the Research-Ethics Commit-
tee of Kuopio University Hospital.
The total number of deliveries during the study period was
23 772, and of those, 9576 women were primiparous and
14 196 women were multiparous. The study material
comprised consecutive 635 sib pairs, both of whom had
their first delivery in the Department of Obstetrics and
Gynecology, Kuopio University Hospital, between Janu-
ary 1989 and December 1999. The data for this study were
prospectively collected, and the case records were retro-
spectively analyzed. In 530 pairs both sisters had normo-
tensive pregnancy and one sister of each sib pair (the one
who gave birth later) was included in the analysis to con-
stitute the reference group. In 63 sib pairs, one of the sis-
ters had preeclampsia in her first pregnancy and study
group I was derived from the unaffected sisters. In 42
pairs, both sisters had preeclampsia and one sister of each
sib pair was incorporated (the one who gave birth later) to
form study group II. All pregnant women were monitored
in an identical manner as outpatients until the develop-
ment of preeclampsia or another pregnancy complication
requiring hospitalization. Basic clinical data were collect-
ed at prenatal visits and at delivery for all the target popu-
lation by the team that took care of treatment.
Hypertensive complications of pregnancy were classified
as advocated by the U.S. National Institute of Health
Working Group on Hypertension in Pregnancy [10].
Preeclampsia wss defined as the development of hyper-
tension and new-onset proteinuria (greater than 300 mg
of urinary protein in 24 h) in women with no proteinuria
at baseline. For those with a baseline diastolic pressure of
90 mmHg, hypertension was defined as a rise of at least 25
mmHg, measured on two consecutive occasions at least
24 h apart. For those with an initial diastolic pressure of
90 mmHg or above, an increament of at least 15 mmHg
was required [11].
For data analysis, the following were used as evidence of
fetal compromise: intrauterine death, admission to a neo-
natal intensive care unit, small-for-gestational -age deliv-
ery, low birth weight, prematurity, low Apgar scores at 1
and 5 min, and fetal acidosis at birth. Reference material
values for the birth weight percentiles were obtained from
own records [12].
Differences between study subjects and the reference
group were tested for significance by using X2 statistics or
Fisher's exact tests, as appropriate. Student's t-test was
used to analyze continuous variables. Differences were
considered to be significant when P < 0.05.
Results
The mean maternal age in study group I (± SD) was 24.3
years (± 4.7 years) and it was 25.5 years (± 4.5 years) in the
reference group (P = 0.04). In study group II, the mean
maternal age was 24.3 years (± 3.4 years) (P = 0.04). Char-
acteristics of women in study groups I and II, who gave
birth at our hospital, during the 10-year period are com-
pared against those of the reference group in Table 1.
Apart from maternal age, the demographic data investigat-
ed in this study were comparable in the three groups.
Table 2. summarizes the frequencies of various pregnancy
and delivery characteristics in the two study groups and in
the control group. Preeclamptic women whose sisters also
Table 1: Maternal Risk Factors
reference group unaffected sisters of preeclamptic 
index patients
affected sisters of preeclamptic 
index patients
risk factor N = 530 N = 63 N = 42
Age < 18 years 14 (2.64%) 2 (3.17%) 1 (2.38%)
Age > 35 years 11 (2.08%) 0 P = 0.617a 0 P = 1.00a
Miscarriage 39 (7.34%) 4 (6.35%) P = 1.00a 5 (11.90%) P = 0.358a
Pregravid body mass index > 25 73 (13.73%) 4 (6.78%) P = 0.134 10 (22.5%) P = 0.129
Unemployed 74 (13.94 %) 7 (11.11 %) P = 0.537 2 (4.76 %) P = 0.092
Not married 244 (46.04%) 21 (33.33%) P = 0.055 14 (33.33%) P = 0.111
IUD before pregnancy 4 (0.75 %) 0 P = 1.00a 0 P = 1.00a
Infertility 27 (5.09 %) 2 (3.17 %) P = 0.758a 3 (7.14 %) P = 0.476a
Smoking (> 5 cigarettes/day) 49 (9.23 %) 2 (3.17 %) P = 0.105 1 (2.38 %) P = 0.162a
Alcohol consumption 17 (3.20 %) 0 P = 0.240a 1 (2.38 %) P = 1.00a
Maternal diabetes 7 (1.32 %) 1 (1.59 %) P = 0.594a 0 P = 1.00a
Chronic illness 25 (4.71 %) 3 (4.76 %) P = 1.00a 1 (2.38 %) P = 0.712a
a Fisher's exact testBMC Women’s Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/1
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had preeclampsia in their first pregnancy underwent ce-
sarean deliveries more often than the control women.
However, the rate of vaginal operative deliveries did not
differ between the groups. 1.59% of the women in study
group I and 0.57% in the reference group had pregnancy-
induced hypertension. Otherwise, the pregnancy charac-
teristics were similar in these groups.
The mean birth weight (± SD) among those delivering at
term (after 37 gestational weeks) was 3530 g (± 444 g) in
the reference group, 3471 g (± 378 g) in study group I (P
= 0.33) and 3398 g (± 494 g) in study group II (P = 0.12).
Table 3. shows the pregnancy outcome measures in the
reference and study groups. As expected, the incidence of
prematurity (P < 0.001), low birth weight (P < 0.001) and
small-for-gestational age infants (P = 0.06) was increased
in sisters affected by preeclampsia (group II), whereas
there was no difference in the rate of fetal death between
the groups. Obstetric outcomes in study group I were
comparable with those in the reference group.
Discussion
The main finding of this study was, that unaffected sisters
of preeclamptic index patients had normal outcomes in
their first pregnancy, the course of pregnancy being com-
parable to that in the general obstetric population. Basi-
cally, no differences were noted in the reproductive risk
factors of the groups studied. Among affected sisters, the
rate of prematurity, low birth weight, and small-for-gesta-
tional age infants were increased, as expected [13]. Al-
though a trial of this size cannot reliably detect differences
in rare complications, such as neonatal death ascribable
to familial risk, the number of cases in the present study is
sufficient to make statistically valid comparisons with re-
gard to commonly used outcome variables. However, it is
not known whether similar changes are present in unaf-
fected first-degree relatives during pregnancy because of
their genetic susceptibility to preeclampsia which in turn
would adversely affect their pregnancies. Any adverse ef-
fect was undetectable in the present study, since only one
(1.59%) of the unaffected women with a first-degree rela-
tive with preeclampsia developed pregnancy-induced hy-
pertension and there were no signs of chronic utero-
placental insufficiency.
Caruso et al. demonstrated in their study of pregnant
women that preeclampsia, but not gestational hyperten-
sion, was characterized by atherogenic metabolic features
similar to those of patients with insulin resistance syn-
drome, such as lower insulin sensitivity, and higher levels
of triglycerides and nonesterified fatty acids [14]. Thus,
the clinical definition seems appropiate, and in clinical
work, preeclampsia phenotypes defined by other criteria
such as glomerular endotheliosis are too difficult to assess
routinely [15].
Preeclampsia is a heterogeneous disorder, and women
with various medical problems are at risk of developing
the disease [16–18]. Many of these conditions are known
to be governed by some components which may have ge-
netic origin, e.g. genetic risks associated with essential
hypertension and diabetes mellitus, and mitochondrial
abnormalities, which in turn, are characterized by micro-
vascular disease [19–21]. Our results may be useful in
counselling patients and their first-degree relatives. Genet-
ic susceptibility to preeclampsia has minor effects, if any,
on pregnancy outcome in first-degree relatives of index
patients, if they do not develop the disease. Basically, rou-
Table 2: Pregnancy and Delivery Characteristics
reference group unaffected sisters of preeclamptic 
index patients
affected sisters of preeclamptic 
index patients
characteristics N = 530 N = 63 N = 42
Pregnancy-induced hypertension 3 (0.57 %) 1 (1.59 %) P = 0.365a 3 (7.14 %) P < 0.001a
Placental abruption 2 (0.38 %) 0 P = 1.00a 1 (2.38 %) P = 0.205a
Placenta previa 4 (0.75 %) 2 (3.17 %) P = 0.126a 0 P = 1.00a
Prolonged gravidarum (>42 w) 39 (7.36 %) 6 (9.52 %) P = 0.612a 1 (2.38 %) P = 0.346a
Female fetus 261 (49.25 %) 30 (47.62 %) P = 0.807 23 (54.76 %) P = 0.491
Isoimmunization (Rh) 1 (0.19 %) 0 P = 1.00a 0 P = 1.00a
Low hemoglobin concentration (< 100 g/L) 7 (1.32 %) 0 P = 1.00a 0 P = 1.00a
Cesarean delivery 97 (18.30 %) 9 (14.29 %) P = 0.432 14 (33.33 %) P = 0.018
Forceps/vacuum 47 (8.87 %) 7 (11.11 %) P = 0.558 2 (4.76 %) P = 0.566a
Bloody amniotic fluid 11 (2.07 %) 2 (3.17 %) P = 0.638a 2 (4.76 %) P = 0.246a
Meconium-stained amniotic fluid 73 (13.75 %) 9 (14.29 %) P = 0.907 4 (9.52 %) P = 0.440
Placental/fetal mass ratio (%) 16.6 % 16.2 % P = 0.51b 17.8 % P = 0.46b
a Fisher's exact test, b Student's t-testBMC Women’s Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/1
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tine antenatal care in which blood pressure and urine dip-
stick are checked each visit is sufficient for women with an
affected sister and there is no need to initiate special fetal
monitoring in these pregnancies. Accordingly, the results
may have implications in genetic linkage studies [22],
since the phenotype in unaffected sisters of preeclamptic
women can be considered normal in terms of clinical out-
come measures. In other words, this observation provides
justification to stratify pregnant women into the catego-
ries of affected and unaffected individuals which is the
current practice in clinical work [23].
Conclusions
The sisters of preeclamptic women are at low risk with re-
gard to adverse pregnancy outcome if they do not develop
preeclampsia. They have pregnancy outcomes compara-
ble to that of the general obstetric population, and routine
antenatal follow-up and management is sufficient in these
cases. Although the etiology and pathogenesis are as yet
unresolved, the complexity of the disease phenotype sup-
ports the theory of a polygenic trait. Women belonging to
the liability group could have considerable pathological
changes in their placental tissue without developing the
maternal syndrome, and this might explain, why such
changes are occasionally observed in fetal growth retarda-
tion, which has also been called normotensive preeclamp-
sia [24]. However, in the present study genetic liability in
unaffected first-degree relatives of preeclamptic index pa-
tients was not associated with any clinical phenotype
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